GlassScriptPhysician profile
Rosa Nogales
NPI 1912911249
$9,356.52
in general payments reported to CMS, 2019-2025
54 companies · $1,219 in 2025
The $1,219 reported for 2025 was more than what 89% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,521 · 2020: $1,456 · 2021: $1,866 · 2022: $990 · 2023: $1,303 · 2024: $1,001 · 2025: $1,219.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,524.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,523.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,226.35 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Abbvie INC. | $1,025.39 | 2020-2025 | |
| Amgen INC. | $902.39 | 2019-2025 | Evenity, Prolia, Otezla |
| Lilly USA, LLC | $544.77 | 2019-2024 | Mounjaro, Jardiance, Zepbound |
| Pfizer INC. | $475.02 | 2019-2025 | |
| Novo Nordisk INC | $429.10 | 2019-2025 | Ozempic, Rybelsus |
| Amarin Pharma, INC. | $344.50 | 2019-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $275.29 | 2019-2025 | Xifaxan |
| Ironwood Pharmaceuticals, INC | $273.90 | 2020-2024 | Linzess |
| Astellas Pharma US INC | $269.25 | 2019-2025 | Veozah, Myrbetriq |
| Allergan, INC. | $250.13 | 2019-2020 | |
| Glaxosmithkline, LLC. | $235.61 | 2020-2025 | Shingrix, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $231.70 | 2019-2025 | Jardiance |
| Kowa Pharmaceuticals America, INC. | $223.13 | 2019-2025 | Zoryve |
| Bayer Healthcare Pharmaceuticals INC. | $191.34 | 2021-2025 |
Show all 54 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rosa Nogales listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.